• Profile
Close

Leydig cell function in male survivors of childhood cancer: A report from the St Jude Lifetime Cohort Study

Journal of Clinical Oncology Nov 18, 2019

Chemaitilly W, Liu Q, van Iersel L, et al. - Given that direct evaluation of Leydig cell function in childhood cancer survivors has been limited, researchers undertook this retrospective analysis with cross-sectional health outcomes analysis, to determine how prevalent are Leydig cell failure (LCF), Leydig cell dysfunction (LCD), and related adverse health outcomes, and to define the factors that confer risk for these in male childhood cancer survivors. Following cancer diagnosis, 1,516 participants with a median age of 30.8 years were assessed at a median of 22.0 years. Serum total testosterone less than 250 ng/dL (or 8.67 nmol/L) and luteinizing hormone greater than 9.85 IU/L defined LCF, and testosterone as 250 ng/dL or greater and luteinizing hormone greater than 9.85 IU/L defined LCD. The prevalence of LCF was estimated to be 6.9% and that of LCD was 14.7%. Findings revealed the link of older age, testicular radiotherapy, and exposure to alkylating agents, with LCF, which was found to be related to adverse physical and psychosexual consequences. Similar risk factors were reported for LCD. There was no link of LCD with adverse health outcomes.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay